Gilead Sciences, Inc.

Gilead Pharmasset LLC

Dominika Pcion

Katie Ann Keaton

Johann Chan

James G Taylor

Dustin S Siegel

Darryl Kato

Adam James Schrier

Michael Sangi

Ruben Martinez

Bruce Ross

Nathan D Shapiro

Olga Viktorovna Lapina

Kapil Kumar Karki

Jonathan Clive Tripp

Henry G Morrison

Peter C Fung

Andrew W Waltman

Denise A Colby

Troy Evan Reynolds

Lina Chan

Donald Tang

Adam Littke

Pamela Seng

Lawrence Yu

Eric Dowdy

Henry Morrison

Chris Levins

Dustin Bringley

Amy Cagulada

Mark Charles Whitcomb

Sudha Kondappally

Sudha Kondapally

Carrie Tomasi

Wenyi Fu

Patricia MacLeod

Eric D Dowdy

Troy Reynolds

Jonathan Tripp

Patricia Macleod

The present disclosure provides processes for the preparation of a compound of formula I: which is useful as an antiviral agent. The disclosure also provides compounds and processes for the preparation of the compounds that are synthetic intermediates to the compound of formula I.

Synthesis of an antiviral compound

Crystalline forms of the anti-HCV compound (1aR,5S,8S,9S,10R,22aR)-5-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-{[(1-methylcyclopropyl)sulfonyl]carbamoyl}cyclopropyl]-9-ethyl-18,18-difluoro-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxamide (Compound I) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using the crystalline forms.

Crystalline forms of an antiviral compound

The invention provides synthetic processes and synthetic intermediates that can be used to prepare 4-oxoquinolone compounds having useful integrase inhibiting properties.

Process and intermediates for preparing integrase inhibitors

Growing community of inventors

San Francisco, CA, United States of America

Dominika Pcion